relatlimab,nivolumab,ipilimumab
bms
['nivolumab', 'nivo', 'ipilimumab', 'melanoma', 'relatlimab']
today at 2023, will present a poster on the efficacy and safety between nivolumab plus relatlimab vs nivolumab plus ipilimumab in advanced #melanoma. 
Leading #cancer treatment, research and patient care. Listen to our podcasts at https://t.co/7IgfJECvU8